

# Philippe Colombat

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5648365/publications.pdf>

Version: 2024-02-01

83  
papers

6,662  
citations

147566

31  
h-index

62479

80  
g-index

88  
all docs

88  
docs citations

88  
times ranked

6227  
citing authors

#	ARTICLE	IF	CITATIONS
1	Investigating a Participatory Intervention in Multidisciplinary Cancer Care Teams Using an Integrative Organizational Model: A Study Protocol. <i>Frontiers in Psychology</i> , 2022, 13, 798863.	1.1	2
2	The Participatory Approach: A Specific French Organizational Model at the Department Level to Serve the Quality of Work Life of Healthcare Providers and the Quality of Care in Pediatric Oncology. <i>Cancer Management and Research</i> , 2021, Volume 13, 2763-2771.	0.9	6
3	Hypercalcemia is associated with a poor prognosis in lymphoma a retrospective monocentric matched-control study and extensive review of published reported cases. <i>Annals of Hematology</i> , 2020, 99, 229-239.	0.8	10
4	The effects of job demands on nurses' burnout and presenteeism through sleep quality and relaxation. <i>Journal of Clinical Nursing</i> , 2020, 29, 583-592.	1.4	58
5	A test of work motivation profile similarity across four distinct samples of employees. <i>Journal of Occupational and Organizational Psychology</i> , 2020, 93, 988-1030.	2.6	19
6	Managerial style and well-being among psychiatric nurses: A prospective study. <i>Journal of Psychiatric and Mental Health Nursing</i> , 2019, 26, 265-273.	1.2	10
7	Nonlinear pharmacokinetics of rituximab in non-Hodgkin lymphomas: A pilot study. <i>British Journal of Clinical Pharmacology</i> , 2019, 85, 2002-2010.	1.1	14
8	Beyond working conditions, psychosocial predictors of job satisfaction, and work engagement among French dentists and dental assistants. <i>Journal of Applied Biobehavioral Research</i> , 2019, 24, e12152.	2.0	10
9	The effects of work factors on nurses' job satisfaction, quality of care and turnover intentions in oncology. <i>Journal of Advanced Nursing</i> , 2018, 74, 1208-1219.	1.5	56
10	Rituximab maintenance versus observation following abbreviated induction with chemoimmunotherapy in elderly patients with previously untreated chronic lymphocytic leukaemia (CLL 2007 SA): an open-label, randomised phase 3 study. <i>Lancet Haematology</i> , 2018, 5, e82-e94.	2.2	23
11	The Role of Workers' Motivational Profiles in Affective and Organizational Factors. <i>Journal of Happiness Studies</i> , 2018, 19, 1151-1174.	1.9	41
12	R-CHOP 14 with or without radiotherapy in nonbulky limited-stage diffuse large B-cell lymphoma. <i>Blood</i> , 2018, 131, 174-181.	0.6	121
13	Organizational and Managerial Resources and Quality of Care in French Pediatric Oncology Nursing. <i>Journal of Pediatric Oncology Nursing</i> , 2017, 34, 406-413.	1.5	9
14	Evaluating abbreviated induction with fludarabine, cyclophosphamide, and dose-dense rituximab in elderly patients with chronic lymphocytic leukemia. <i>Leukemia and Lymphoma</i> , 2016, 57, 328-334.	0.6	9
15	Burnout syndrome in oncology and hematology healthcare professionals. <i>Hematologie</i> , 2015, 21, 280-288.	0.0	6
16	Emergence of community-acquired <i>Clostridium difficile</i> infection: the experience of a French hospital and review of the literature. <i>International Journal of Infectious Diseases</i> , 2015, 37, 36-41.	1.5	41
17	Decisional Early Interim 18F-Fluoro-2-Deoxy-D-Glucose Positron Emission Tomography after Two Cycles of Chemotherapy in de novo Hodgkin Lymphoma. <i>Acta Haematologica</i> , 2015, 133, 172-178.	0.7	4
18	Do Transactive Memory and Participative Teamwork Improve Nurses' Quality of Work Life?. <i>Western Journal of Nursing Research</i> , 2014, 36, 329-345.	0.6	15

#	ARTICLE	IF	CITATIONS
19	Could a citrus keep the haematologist away?. British Journal of Haematology, 2014, 166, 298-300.	1.2	1
20	A phase 1 dose escalation study of idarubicin combined with methotrexate, vindesine, and prednisolone for untreated elderly patients with primary central nervous system lymphoma: The GOELAMS LCP 99 trial. American Journal of Hematology, 2014, 89, 1024-1029.	2.0	21
21	Interferon alpha with or without rituximab achieves a high response rate and durable responses in relapsed FL: 17 years' experience in a single centre. Annals of Hematology, 2014, 93, 147-156.	0.8	6
22	t(14;18) Translocation: A Predictive Blood Biomarker for Follicular Lymphoma. Journal of Clinical Oncology, 2014, 32, 1347-1355.	0.8	115
23	Publi� dans H�matologie vol. 11, n�1, janvier-f�vrier 2005. Hematologie, 2014, 20, 12-21.	0.0	8
24	The participative approach in the care: a model inspired by hematology. Hematologie, 2014, 20, 258-263.	0.0	2
25	The mediating role of organizational justice in the relationship between transformational leadership and nurses' quality of work life: A cross-sectional questionnaire survey. International Journal of Nursing Studies, 2013, 50, 1359-1367.	2.5	115
26	Intermediate stage Hodgkin lymphoma in partial remission after three or four courses of doxorubicin, bleomycin, vinblastine dacarbazine: no benefit of one course of intensive chemotherapy before irradiation. Leukemia and Lymphoma, 2013, 54, 76-82.	0.6	0
27	Procedural justice, supervisor autonomy support, work satisfaction, organizational identification and job performance: the mediating role of need satisfaction and perceived organizational support. Journal of Advanced Nursing, 2013, 69, 2560-2571.	1.5	114
28	Perceived organizational support, motivation, and engagement among police officers.. Professional Psychology: Research and Practice, 2013, 44, 46-55.	0.6	107
29	A Randomized Study of Interferon � Versus No Treatment as Consolidation After High Dose Therapy and Autologous Stem Cell Transplantation for Patients With Relapsed Lymphoma. Oncologist, 2013, 18, 1189-1189.	1.9	5
30	Impact of [ <sup>18</sup> F]Fluorodeoxyglucose Positron Emission Tomography Response Evaluation in Patients With High Tumor Burden Follicular Lymphoma Treated With Immunochemotherapy: A Prospective Study From the Groupe d'Etudes des Lymphomes de l'Adulte and GOELAMS. Journal of Clinical Oncology, 2012, 30, 4317-4322.	0.8	168
31	The Impact of Organizational Factors on Psychological Needs and Their Relations with Well-Being. Journal of Business and Psychology, 2012, 27, 437-450.	2.5	179
32	Relationships between the characteristics of oncohematology services providing palliative care and the sociodemographic characteristics of caregivers using health indicators: social support, perceived stress, coping strategies, and quality of work life. Supportive Care in Cancer, 2012, 20, 607-614.	1.0	25
33	Safety and Efficacy of Abbreviated Induction with Oral Fludarabine (F) and Cyclophosphamide (C) Combined with Dose-Dense IV Rituximab (R) in Previously Untreated Patients with Chronic Lymphocytic Leukemia (CLL) Aged > 65 years : Results of a Multicenter Trial (LLC 2007 SA) On Behalf of the French Goelams/Fcgcll-WM Intergroup. Blood, 2012, 120, 434-434.	0.6	12
34	Evaluation of the (R)VAD+C regimen for the treatment of newly diagnosed mantle cell lymphoma. Combined results of two prospective phase II trials from the French GOELAMS group. Haematologica, 2010, 95, 1350-1357.	1.7	36
35	Rapid and durable molecular response of refractory T-cell large granular lymphocyte leukemia after alemtuzumab treatment. Leukemia Research, 2010, 34, e197-e199.	0.4	8
36	Juvenile xanthogranuloma with hematological dysfunction treated with 2CDA�AraC. Pediatric Blood and Cancer, 2010, 55, 757-760.	0.8	10

#	ARTICLE	IF	CITATIONS
37	Influence of methotrexate exposure on outcome in patients treated with MBVP chemotherapy for primary central nervous system lymphoma. <i>British Journal of Clinical Pharmacology</i> , 2010, 70, 367-375.	1.1	9
38	Upfront VIPâ€reinforcedâ€ABVD (VIPâ€rABVD) is not superior to CHOP/21 in newly diagnosed peripheral T cell lymphoma. Results of the randomized phase III trial GOELAMSâ€LTP95. <i>British Journal of Haematology</i> , 2010, 151, 159-166.	1.2	137
39	La transfusion dansÂlesÂhÃ©mopathies enÂfin deÂvie: aspects Ã©thiques etÂorganisationnels. <i>Hematologie</i> , 2010, 16, 228-234.	0.0	6
40	High-dose therapy followed by autologous purged stem cell transplantation and doxorubicin-based chemotherapy in patients with advanced follicular lymphoma: a randomized multicenter study by the GOELAMS with final results after a median follow-up of 9 years. <i>Blood</i> , 2009, 113, 995-1001.	0.6	144
41	High-dose therapy and autologous stem cell transplantation versus conventional therapy for patients with advanced Hodgkin's lymphoma responding to front-line therapy: long-term results. <i>Haematologica</i> , 2009, 94, 146-148.	1.7	66
42	Phase I/II Study of Escalating Doses of Idarubicin in Combination with Methotrexate, Vindesine and Prednisolone in Patients with Primary Central Nervous System Lymphoma: Results of the GOELAMS LCP99 Multicenter Trial.. <i>Blood</i> , 2009, 114, 2694-2694.	0.6	2
43	Late Relapse of Localized High-Grade Non-Hodgkinâ€™s Lymphoma: Clinical and Biological Features. <i>Blood</i> , 2008, 112, 2603-2603.	0.6	2
44	High-Dose Chemotherapy Followed by Autologous Stem Cell Transplantation (auto-SCT) Versus CHOP Regimen in Patients with Untreated Aggressive Non-Hodgkinâ€™s Lymphoma: An Update of the GOELAMS 072 Trial with a Median Follow-up of 9.8 Years. <i>Blood</i> , 2008, 112, 770-770.	0.6	11
45	The Role of Platelet/Endothelial Cell Adhesion Moleculeâ€1 (CD31) and CD38 Antigens in Marrow Microenvironmental Retention of Acute Myelogenous Leukemia Cells. <i>Cancer Research</i> , 2007, 67, 8624-8632.	0.4	32
46	A uniform activated B-cellâ€like immunophenotype might explain the poor prognosis of primary central nervous system lymphomas: analysis of 83 cases. <i>Blood</i> , 2006, 107, 190-196.	0.6	335
47	CXCL12 polymorphism and malignant cell dissemination/tissue infiltration in acute myeloid leukemia. <i>FASEB Journal</i> , 2006, 20, 1913-1915.	0.2	49
48	The VIP-ABVD Regimen Is Not Superior to the CHOP 21 for the Treatment of Non Epidermotropic Peripheral T Cell Lymphoma. Final Results of the â€LTP95â€ Protocol of the GOELAMS.. <i>Blood</i> , 2006, 108, 2464-2464.	0.6	9
49	Single Treatment with Rituximab Monotherapy for Low-Tumor Burden Follicular Lymphoma (FL): Survival Analyses with Extended Follow-Up (F/Up) of 7 Years.. <i>Blood</i> , 2006, 108, 486-486.	0.6	41
50	The Extramedullar Dissemination of Acute Myeloid Leukemic Cells Depends on CD31 (PECAM-1) and CD38 Coexpression Level.. <i>Blood</i> , 2006, 108, 1896-1896.	0.6	1
51	High-dose therapy followed by autologous purged stem-cell transplantation and doxorubicin-based chemotherapy in patients with advanced follicular lymphoma: a randomized multicenter study by GOELAMS. <i>Blood</i> , 2005, 105, 3817-3823.	0.6	176
52	Preliminary Results of a Prospective Randomized Study Comparing First Line Conventional Therapy Versus High Dose Therapy with Autologous CD34+ Purified Progenitor Cell Support in B CLL Patients with B and C Binet Stages: The GOELAMS LLC98 Study.. <i>Blood</i> , 2005, 106, 152-152.	0.6	5
53	Rituximab-Dependent Cytotoxicity by Natural Killer Cells. <i>Cancer Research</i> , 2004, 64, 4664-4669.	0.4	395
54	Initial Treatment of Aggressive Lymphoma with High-Dose Chemotherapy and Autologous Stem-Cell Support. <i>New England Journal of Medicine</i> , 2004, 350, 1287-1295.	13.9	324

#	ARTICLE	IF	CITATIONS
55	Single 4-Dose Rituximab Treatment for Low-Tumor Burden Follicular Lymphoma (FL): Survival Analyses with a Follow-Up (F/Up) of at Least 5 Years.. <i>Blood</i> , 2004, 104, 585-585.	0.6	12
56	Rituximab Given after High Dose Therapy and Autologous Stem Cell Transplantation Induces Durable Clearance of Minimal Residual Disease in about Half of the Patients with Follicular Non Hodgkin's Lymphoma : 36 Months Results of a Multicenter Open Label Phase II Trial (M39012 Trial).. <i>Blood</i> , 2004, 104, 747-747.	0.6	5
57	Front-Line High-Dose Chemotherapy (HDT) Combined with Rituximab for Adults with Aggressive Large B-Cell Lymphoma (DLBCL) : Goelams 074 Trial.. <i>Blood</i> , 2004, 104, 902-902.	0.6	2
58	Long-term marrow reconstitutive ability of autologous grafts in lymphoma patients using peripheral blood mobilized with granulocyte colony-stimulating factor or granulocyte-macrophage colony-stimulating factor compared to bone marrow. <i>Experimental Hematology</i> , 2003, 31, 89-97.	0.2	8
59	Stromal-derived factor 1 and matrix metalloproteinase 9 levels in bone marrow and peripheral blood of patients mobilized by granulocyte colony-stimulating factor and chemotherapy. Relationship with mobilizing capacity of haematopoietic progenitor cells. <i>British Journal of Haematology</i> , 2003, 122, 918-926.	1.2	40
60	High-Dose Therapy and Autologous Stem-Cell Transplantation Versus Conventional Therapy for Patients With Advanced Hodgkin's Lymphoma Responding to Front-Line Therapy. <i>Journal of Clinical Oncology</i> , 2003, 21, 2320-2325.	0.8	106
61	Quantitative and Qualitative Analysis of the Human Primitive Progenitor Cell Compartment after Autologous Stem Cell Transplantation. <i>Journal of Hematotherapy and Stem Cell Research</i> , 2002, 11, 359-368.	1.8	8
62	Decreased Stroma Adhesion Capacity of CD34+Progenitor Cells from Mobilized Peripheral Blood Is Not Lineage- or Stage-Specific and Is Associated with Low $\beta$ 1 and $\beta$ 2 Integrin Expression. <i>Journal of Hematotherapy and Stem Cell Research</i> , 2002, 11, 491-500.	1.8	16
63	Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor Fc $\gamma$ R3 gene. <i>Blood</i> , 2002, 99, 754-758.	0.6	1,819
64	Stage I/II Primary Non-Hodgkin's Lymphoma of the Testis: Results of a Prospective Trial by the GOELAMS Study Group. <i>Clinical Lymphoma and Myeloma</i> , 2002, 3, 167-172.	2.1	58
65	Frequency and differentiation capacity of circulating LTC-IC mobilized by G-CSF or GM-CSF following chemotherapy A comparison with steady-state bone marrow and peripheral blood. <i>Experimental Hematology</i> , 2002, 30, 74-81.	0.2	16
66	All-trans retinoic acid prevents apoptosis of human marrow CD34+ cells deprived of haematopoietic growth factors. <i>British Journal of Haematology</i> , 2002, 118, 289-295.	1.2	8
67	Phosphatidylinositol 3-kinases are involved in the all-transretinoic acid-induced upregulation of CD38 antigen on human haematopoietic cells. <i>British Journal of Haematology</i> , 2002, 118, 535-544.	1.2	12
68	Induction of monocyte tissue factor expression by antibodies to heparin-platelet factor 4 complexes developed in heparin-induced thrombocytopenia. <i>Blood</i> , 2001, 97, 3300-3302.	0.6	191
69	Association between the SDF1- 3' allele and high levels of CD34+ progenitor cells mobilized into peripheral blood in humans. <i>British Journal of Haematology</i> , 2001, 113, 247-250.	1.2	65
70	Multiple myeloma in elderly patients: presenting features and outcome. <i>European Journal of Haematology</i> , 2001, 66, 11-17.	1.1	35
71	Glimepiride-Induced Thrombocytopenic Purpura. <i>Annals of Pharmacotherapy</i> , 2000, 34, 120-120.	0.9	23
72	Comparison of High-Dose Therapy and Autologous Stem-Cell Transplantation With Conventional Therapy for Hodgkin's Disease Induction Failure: A Case-Control Study. <i>Journal of Clinical Oncology</i> , 1999, 17, 222-222.	0.8	147

#	ARTICLE	IF	CITATIONS
73	Intensive Therapy with Autologous Stem Cell Transplantation as First-Line Therapy in Poor-Risk Hodgkin's Disease and Analysis of Predictive Factors of Outcome. <i>Leukemia and Lymphoma</i> , 1999, 34, 305-313.	0.6	6
74	A rapid single-laser flow cytometric method for discrimination of early apoptotic cells in a heterogenous cell population. <i>British Journal of Haematology</i> , 1999, 104, 530-537.	1.2	70
75	All-trans-retinoic acid up-regulates CD38 but not c-Kit antigens on human marrow CD34+cells without recruitment into cell cycle. <i>British Journal of Haematology</i> , 1998, 103, 343-350.	1.2	10
76	Mediastinal Large-Cell Lymphoma with Sclerosis Refractory to Conventional Chemotherapy can Respond after Daily Oral Cyclophosphamide. <i>Leukemia and Lymphoma</i> , 1998, 29, 199-203.	0.6	1
77	Changes in the Functional Capacity of Marrow Stromal Cells after Autologous Bone Marrow Transplantation. <i>Leukemia and Lymphoma</i> , 1998, 29, 533-546.	0.6	29
78	Cytokines released <i>in vitro</i> by stromal cells from autologous bone marrow transplant patients with lymphoid malignancy. <i>European Journal of Haematology</i> , 1998, 61, 100-108.	1.1	12
79	Development of Listeriosis during Vancomycin Therapy in a Neutropenic Patient. <i>Scandinavian Journal of Infectious Diseases</i> , 1996, 28, 415-416.	1.5	6
80	High-Dose Therapy and Autologous Bone Marrow Transplantation in First Complete or Partial Remission for Poor Prognosis Hodgkin's Disease. <i>Leukemia and Lymphoma</i> , 1996, 20, 259-266.	0.6	19
81	Simultaneous occurrence of acute myelogenous leukemia and seminoma of the testis. <i>Cancer Chemotherapy and Pharmacology</i> , 1992, 30, 233-234.	1.1	5
82	Cutaneous toxicity of autologous bone marrow transplantation in nonseminomatous germ cell tumors. <i>Cancer</i> , 1990, 65, 1143-1145.	2.0	4
83	High-Dose Therapy and Autologous Bone Marrow Transplantation after Failure of Conventional Chemotherapy in Adults with Intermediate-Grade or High-Grade Non-Hodgkin's Lymphoma. <i>New England Journal of Medicine</i> , 1987, 316, 1493-1498.	13.9	767